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Abstract
Background: A key step in the design of a RCT is the estimation of the number of participants needed in the study.
The most common approach is to specify a target difference between the treatments for the primary outcome and
then calculate the required sample size. The sample size is chosen to ensure that the trial will have a high probability
(adequate statistical power) of detecting a target difference between the treatments should one exist.
The sample size has many implications for the conduct and interpretation of the study. Despite the critical role that the
target difference has in the design of a RCT, the way in which it is determined has received little attention. In this
article, we summarise the key considerations and messages from new guidance for researchers and funders on
specifying the target difference, and undertaking and reporting a RCT sample size calculation. This article on
choosing the target difference for a randomised controlled trial (RCT) and undertaking and reporting the sample
size calculation has been dual published in the BMJ and BMC Trials journals
Methods: The DELTA2 (Difference ELicitation in TriAls) project comprised five major components: systematic literature
reviews of recent methodological developments (stage 1) and existing funder guidance (stage 2); a Delphi study
(stage 3); a two-day consensus meeting bringing together researchers, funders and patient representatives (stage 4);
and the preparation and dissemination of a guidance document (stage 5).
Results and Discussion: The key messages from the DELTA2 guidance on determining the target difference and
sample size calculation for a randomised caontrolled trial are presented. Recommendations for the subsequent
reporting of the sample size calculation are also provided.
Background
Properly conducted, the RCT is generally considered to
be the gold standard for assessing the comparative clin-
ical efficacy and effectiveness of healthcare interventions,
as well as providing a key source of data for estimating
cost-effectiveness [1]. These trials are routinely used to
evaluate a wide range of treatments and have been
successfully used in a variety of health and social care
settings. Central to the design of a RCT is an a-priori
sample size calculation, which ensures the study has a
high probability of achieving its pre-specified objectives.
The difference between groups used to calculate a sam-
ple size for the trial, the “target difference”, is the magni-
tude of difference in the outcome of interest that the RCT
is designed to reliably detect. Reassurance in this regard is
typically confirmed by having a sample size which has a
sufficiently high level of statistical power (typically 80 or
90%) for detecting a difference as big as the target
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difference, while setting the statistical significance at the
level planned for the statistical analysis (usually this is the
2-sided 5% level). A comprehensive methodological review
conducted by the original DELTA (Difference ELicitation
in TriAls) group [2, 3] highlighted the available methods
and limitations in current practice. It showed that despite
there being many different approaches available, some are
used only rarely in practice [4]. The initial DELTA guid-
ance does not fully meet the needs of funders and re-
searchers. The overall aim of the DELTA2 project,
commissioned by the UK Medical Research Council
(MRC)/National Institute for Health Research (NIHR)
Methodology Research Programme (MRP), and described
here, was to produce updated guidance for researchers
and funders on specifying and reporting the target
difference (“effect size”) in the sample size calculation
of a RCT. In this article, we summarise the process of
developing the new guidance, as well as the relevant con-
siderations, key messages and recommendations for deter-
mining and reporting a RCT’s sample size calculation
(Tables 1 and 2). This article on choosing the target differ-
ence for a randomised controlled trial (RCT) and under-
taking and reporting the sample size calculatio has been
dak published in tge BMJ and BMC Trials journals.
Development of the DELTA2 guidance
The DELTA2 guidance is the culmination of a five stage
process to meet the stated project objectives (see Fig. 1)
which included two literature reviews of existing funder
guidance and recent methodological literature, a Delphi
process to engage with a wider group of stakeholders, a
2 day workshop and finalising the core guidance.
The literature review was conducted between April and
December 2016 (searching up to April 2016). The Delphi
study had two rounds: one held in 2016 before a two-day
workshop in Oxford (September 2016) and another be-
tween August and November 2017. The general structure
of the guidance was devised at the workshop. It was sub-
stantially revised based upon feedback from stakeholders
received through the Delphi study. In addition, stake-
holder engagement events were held at various meetings
throughout the development of the guidance: the Society
for Clinical Trials (SCT) meeting, and Statisticians in the
Pharmaceutical Industry (PSI) conferences both in May
2017, Joint Statistical Meeting (JSM) in August 2017 and a
Royal Statistical Society (RSS) Reading local group meet-
ing in September 2017. These interactive sessions pro-
vided feedback on the scope (in 2016) and then draft
guidance (in 2017). The core guidance was provisionally
finalised in October 2017 and reviewed by the funders’
representatives for comment (MRP advisory group). The
guidance was further revised and finalised in February
2018. The full guidance document incorporating case
studies and relevant appendices is available here [5].
Further details on the findings of the Delphi study and the
wider engagement with stakeholders are reported else-
where [6]. The guidance and key messages are sum-
marised in the remainder of the paper.
The target difference and sample size calculations in RCTs
The role of the sample size calculation is to determine
how many patients are required for the planned analysis
Table 1 DELTA2 recommendations undertaking a sample size
calculation and choosing the target difference for a RCT
Begin by searching for relevant literature to inform the specification of
the target difference. Relevant literature can:
a. relate to a candidate primary outcome and/or the comparison of
interest, and;
b. inform what is an important and/or realistic difference for that
outcome, comparison and population.
2. Candidate primary outcomes should be considered in turn, and the
corresponding sample size explored. Where multiple candidate
outcomes are considered, the choice of the primary outcome and
target difference should be based upon consideration of the views of
relevant stakeholders groups (for example, patients), as well as the
practicality of undertaking such a study with the required sample size.
The choice should not be based solely on which yields the minimum
sample size. Ideally, the final sample size will be sufficient for all key
outcomes though this is not always practical.
3. The importance of observing a particular magnitude of a difference
in an outcome, with the exception of mortality and other serious
adverse events, cannot be presumed to be self-evident. Therefore, the
target difference for all other outcomes requires additional justification
to infer importance to a stakeholder group.
4. The target difference for a definitive (e.g. Phase III) trial should be
one considered to be important to at least one key stakeholder group.
5. The target difference does not necessarily have to be the minimum
value that would be considered important if a larger difference is
considered a realistic possibility or would be necessary to alter practice.
6. Where additional research is needed to inform what would be an
important difference, the anchor and opinion seeking methods are to
be favoured. The distribution method should not be used. Specifying
the target difference based solely upon a Standardised Effect Size
approach should be considered a last resort though it may be helpful
as a secondary approach.
7. Where additional research is needed to inform what would be a
realistic difference, the Opinion Seeking and the Review of the
Evidence Base methods are recommended. Pilot trials are typically
too small to inform what would be a realistic difference and primarily
address other aspects of trial design and conduct.
8. Use existing studies to inform the value of key “nuisance” parameters
which are part of the sample size calculation. For example, a pilot trial
can be used to inform the choice of the standard deviation value for a
continuous outcome and the control group proportion for a binary
outcome, along with other relevant inputs such as the amount of
missing outcome data.
9. Sensitivity analyses, which consider the impact of uncertainty around
key inputs (e.g. the target difference and the control group proportion
for a binary outcome) used in the sample size calculation, should be
carried out.
10. Specification of the sample size calculation, including the target
difference, should be reported according to the guidance for reporting
items (see below) when preparing key trial documents (grant applications,
protocols and result manuscripts).
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of the primary outcome to be informative. It is typically
achieved by specifying a target difference for the key
(primary) outcome which can be reliably detected and
the required sample size calculated. In this summary
paper we restrict considerations to the most common
trial design looking at a superiority question (one which
assumes no difference and looks for a difference), although
the full guidance considers equivalence and non-inferiority
designs which invert the hypothesis and how the use of the
target difference differs for such designs [5].
Table 2 DELTA2 recommended reporting items for the sample size calculation of a RCT with a superiority question
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The precise research question that the trial is primarily
set up to answer will determine what needs to be esti-
mated in the planned primary analysis, this is known
formally as the ‘estimand’. A key part of deciding this is
choosing the primary outcome, which requires careful
consideration. The target difference should be a differ-
ence that is appropriate for that estimand [7–10]. Typic-
ally (for superiority trials), an “intention to treat” or
treatment policy estimand - that is, according to the ran-
domised groups irrespective of subsequent compliance
with the treatment allocation - is used. Other analyses
that address different estimands [8, 9, 11] of interest (e.g.
those based on the effect upon receipt of treatment and
the absence of non-compliance) could also inform the
choice of sample size. Different stakeholders can have
somewhat differing perspectives on the appropriate tar-
get difference [12]. However, a key principle is that the
target difference should be one that would be viewed as
important by at least one (and preferably more) key
stakeholder groups that is, patients, health professionals,
regulatory agencies, and healthcare funders. In practice,
the target difference is not always formally considered
and in many cases appears, at least from trial reports, to
be determined upon convenience, the research budget,
or some other informal basis [13]. The target difference
can be expressed as an absolute difference (e.g., mean
difference or difference in proportions) or a relative dif-
ference (e.g., hazard or risk ratio), and it is also often re-
ferred to, rather imprecisely, as the trial “effect size”.
Statistical calculation of the sample size is far from an
exact science [14]. Firstly, investigators typically make
assumptions that are a simplification of the anticipated
analysis. For example, the impact of adjusting for base-
line factors is very difficult to quantify upfront, and even
though the analysis is intended to be an adjusted one
(such as when randomisation has been stratified or mini-
mised), [15] the sample size calculation is often con-
ducted based on an unadjusted analysis. Secondly, the
calculated sample size can be sensitive to the assump-
tions made in the calculations such that a small change
in one of the assumptions can lead to substantial change
in the calculated sample size. Often a simple formula
can be used to calculate the required sample size. The
formula varies according to the type of outcome, how
the target difference is expressed (e.g. a risk ratio versus
a difference in proportions), and somewhat implicitly the
design of the trial and the planned analysis. Typically, a
sample size formula can be used to calculate the re-
quired number of observations in the analysis set, which
varies depending on the outcome and the intended ana-
lysis. In some situations, ensuring the sample size is suf-
ficient for more than one planned analysis may be
appropriate.
When deciding upon the sample size for a RCT, it is
necessary to balance the risk of incorrectly concluding
there is a difference when no actual difference between
the treatments exists, with the risk of failing to identify a
meaningful treatment difference when the treatments do
differ. Under the conventional approach, referred to as
the statistical hypothesis testing framework [16], the
probabilities of these two errors are controlled by setting
the significance level (Type I error) and statistical power
(1 minus Type II error) at appropriate levels (typical
values are 2 sided 5% significance and 80% or 90% power
respectively). Once these two inputs have been set, the
sample size can be determined given the magnitude of
the between group difference in the outcome it is de-
sired to detect (the target difference). The calculation
(reflecting the intended analysis) is conventionally done
on the basis of testing for a difference of any magnitude.
As a consequence, it is essential when interpreting the
analysis of a trial to consider the uncertainty in the esti-
mate, which is reflected in the confidence interval. A key
question of interest is what magnitude of difference can
be ruled out. The expected (predicted) width of the con-
fidence interval can be determined for a given target dif-
ference and sample size calculation which is a helpful
further aid in making an informed choice about this part
of a trial’s design [17]. Other statistical and economic
approaches to calculating the sample size have been pro-
posed such as precision and Bayesian based approaches,
[16, 18–20] and value of information analysis, [21]
though they are not at present commonly applied [22].
The required sample size is very sensitive to the target
difference. Under the conventional approach, halving the
target difference quadruples the sample size for a two arm
1:1 parallel group superiority trial with a continuous out-
come [23]. Appropriate sample size formulae vary de-
pending upon the proposed trial design and statistical
analysis, although the overall approach is consistent. In
more complex scenarios, simulations may be used but the
same general principles hold. It is prudent to undertake
Fig. 1 DELTA2 project components of work
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sensitivity calculations to assess the potential effect of mis-
specification of key assumptions (such as the control re-
sponse rate for a binary outcome or the anticipated
variance of a continuous outcome).
The sample size calculation and the target difference,
if well specified, help provide reassurance that the trial is
likely to detect a difference at least as large as the target
difference in terms of comparing the primary outcome
between treatments. Failure to clarify sufficiently what is
important and realistic at the design stage can lead to
subsequent sample size revisions, an unnecessarily in-
conclusive trial due to lack of statistical precision, or to
ambiguous interpretation of the findings [24, 25]. When
specifying the target difference with a definitive trial in
mind, the following guidance should be considered.
Specifying the target difference for a randomised
controlled trial
Different statistical approaches can be taken to specify
the target difference and calculate the sample size but
the general principles are the same. To aid those new to
the topic and to encourage better practice and reporting
regarding the specification of the target difference for a
RCT, a series of recommendations is provided in Tables 1
and 2. Seven broad types of methods can be used to jus-
tify the choice of a particular value as the target differ-
ence: these are summarised in Table 3.
Broadly speaking, two different approaches can be
taken to specify the target difference for a RCT. A differ-
ence that is considered to be:
 important to one or more stakeholder groups
 realistic (plausible), based on either existing
evidence, or expert opinion.
A very large literature exists on defining and justifying
a (clinically) important difference, particularly for quality
of life outcomes [26–28]. In a similar manner, discus-
sions of the relevance of estimates from existing studies
are also common; there are a number of potential pitfalls
to their use, which requires careful consideration of how
they should inform the choice of the target difference
[2]. It has been argued that a target difference should al-
ways be both important and realistic [29], which would
seem particularly apt when designing a definitive (Phase
III) superiority RCT. In a sample size calculation for a
RCT, the target difference between the treatment
groups, strictly relates to a group level difference for the
anticipated study population. However, the difference in
an outcome that is important to an individual might dif-
fer from the corresponding value at the population level.
More extensive consideration of the variations in ap-
proach is provided elsewhere [3, 30].
Reporting the sample size calculation
The approach taken when determining the sample size
and the assumptions made should be clearly specified.
This information should include all the inputs and for-
mula or simulation results, so that it is clear what the
sample size was based upon. This information is critical
Table 3 Methods that can be used to inform the choice of the
target difference
Methods that inform what is an important difference
Anchor: The outcome of interest can be “anchored” by using either a
patient’s or health professional’s judgement to define what an
important difference is. This may be achieved by comparing a patient’s
health before and after treatment and then linking this change to
participants who showed improvement/deterioration using a more
familiar outcome (for which either patients or health professionals more
readily agree on what amount of change constitutes an important
difference).. Contrasts between patients (e.g., individuals with varying
severity of a disease) can also be used to determine a meaningful difference.
Distribution: Approaches that determine a value based upon
distributional variation. A common approach is to use a value that is
larger than the inherent imprecision in the measurement and therefore
likely to represent a minimal level needed for a noticeable difference.
Health economic: Approaches that use principles of economic evaluation.
These compare cost with health outcomes, and define a threshold value
for the cost of a unit of health effect that a decision-maker is willing to
pay, to estimate the overall incremental net benefit of one treatment
versus the comparator. A study can be powered to exclude a zero
incremental net benefit at a desired statistical significance and power.
A radically different approach is a (Bayesian) decision-theoretic value of
information analysis which compares the added value with the added
cost of the marginal observation, thus avoiding the need to specify a
target difference.
Standardised effect size: The magnitude of the effect on a standardised
scale defines the value of the difference. For a continuous outcome, the
standardised difference (most commonly expressed as Cohen’s d “effect
size”, the mean difference dividing by the standard deviation) can be
used. Cohen’s cutoffs of 0.2, 0.5, and 0.8 for small, medium, and large
effects, respectively, are often used. Thus a “medium” effect corresponds
simply to a change in the outcome of 0.5 SDs. When measuring a
binary or survival (time-to-event) outcome alternative metrics
(e.g., an odds, risk, or hazard ratio) can be utilised in a similar manner,
though no widely recognised cut-points exist. Cohen’s cut-points
approximate odds ratios of 1.44, 2.48, and 4.27, respectively. Corresponding
risk ratio values vary according to the control group event proportion.
Methods that inform what is a realistic difference
Pilot study: A pilot (or preliminary) study may be carried out where there
is little evidence, or even experience, to guide expectations and determine
an appropriate target difference for the trial. In a similar manner, a Phase 2
study could be used to inform a Phase 3 study though this would need to
take account of methodological differences (e.g. inclusion criteria and
outcomes) that should be reflected in specification of the target difference.
Methods that inform what is an important and/or a realistic difference
Opinion-seeking: The target difference can be based on opinions elicited
from health professionals, patients, or others. Possible approaches include
forming a panel of experts, surveying the membership of a professional or
patient body, or interviewing individuals. This elicitation process can be
explicitly framed within a trial context.
Review of evidence base: The target difference can be derived from
current evidence on the research question. Ideally, this would be from a
systematic review or meta-analysis of RCTs. In the absence of randomised
evidence, evidence from observational studies could be used in a similar
manner.
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for reporting transparency, allows the sample size calcu-
lation to be replicated, and clarifies the primary (statis-
tical) aim of the study. Under the conventional approach
with a standard (1:1 allocation two arm parallel group
superiority) trial design and unadjusted statistical ana-
lysis, the core items needed to be stated are the primary
outcome, the target difference appropriately specified ac-
cording to the outcome type, the associated “nuisance”
parameter (that is, a parameter that, together with the
target difference, uniquely specifies the difference on the
original outcome scale—eg, the event rate in the control
group for a binary primary outcome), and the statistical
significance and power. More complicated designs can
have additional inputs that also need considered, like the
intra-cluster correlation for a cluster randomised design.
A set of core items should be reported in all key trial
documents (grant applications, protocols and main re-
sults papers) to ensure reproducibility and plausibility of
the sample size calculation. The full list of recom-
mended core items are given in Table 2 which is an up-
date of the previously-proposed list [31]. When the
sample size calculation deviates from the conventional
approach, whether by research question or statistical
framework, the core reporting set may be modified to
provide sufficient detail to ensure the sample size calcu-
lation is reproducible and the rationale for choosing the
target difference is transparent. However, the key princi-
ples remain the same. If the sample size is determined
based upon a series of simulations, this would need to
be described in sufficient detail to enable equivalent level
of transparency and assessment. Additional items to give
more explanation of the rationale should be provided
where space allows (e.g. grant applications and trial pro-
tocols). Trial result publications can then reference these
documents if sufficient space is not available to provide
a full description.
Discussion
Researchers are faced with a number of difficult deci-
sions when designing a RCT, the most important of
which are the choice of trial design, primary outcome
and sample size. The latter is largely driven by the
choice of the target difference, although other aspects of
sample size determination also contribute.
The DELTA2 guidance provides help on specifying a
target difference and undertaking and reporting the sample
size calculation for a RCT. The guidance was developed in
response to a growing recognition from funders, re-
searchers, as well as other key stakeholders (such as pa-
tients and the respective clinical communities) of a real
need for practical and accessible advice to inform a difficult
decision. The new guidance document therefore aims to
bridge the gap between the existing (limited) guidance and
this growing need.
The key message for researchers is the need to be
more explicit about the rationale and justification of the
target difference when undertaking and reporting a sam-
ple size calculation. Increasing focus is being placed
upon the target difference in the clinical interpretation
of the trial result, whether statistically significant or not.
Therefore the specification and reporting of the target
difference, and other aspects of the sample size calcula-
tio, needs to be improved.
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